OZMOSI and Planview Partner to Integrate AI Planning in Pharma R&D

April 23, 2026
OZMOSI and Planview have announced a partnership to connect structured clinical data with AI portfolio planning, enabling pharmaceutical teams to make faster and more informed R&D decisions.

OZMOSI and Planview have announced a strategic partnership to connect structured clinical intelligence with AI portfolio planning in pharmaceutical research and development according to a press release.

The collaboration integrates OZMOSI's machine readable clinical datasets into Planview's AI portfolio planning platform, linking external scientific data with internal R&D operations. This connection allows pharmaceutical organizations to better predict market changes, prioritize investments, and make faster decisions based on standardized data.

OZMOSI provides structured intelligence from over 800,000 clinical trials, 35,000 drugs, and 4,000 diseases, consolidating data from regulatory filings, scientific literature, and company disclosures. Planview’s platform enables modeling of investment scenarios and alignment of initiatives with corporate strategy. Together, the companies aim to give pharmaceutical teams a unified view of the R&D landscape supported by AI analysis.

The integration is designed to enhance portfolio visibility by combining internal planning data with continuously updated external clinical insights, helping organizations evaluate competition, identify trends, and simulate outcomes more accurately.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Enterprise AI Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Enterprise

04/23
Akeyless Appoints Yael Fainaro as Chief Strategy Officer to Expand AI Identity Security Ecosystem
04/23
VSBLTY and Brightside Partner on AI and Satellite Projects in the Philippines
04/23
Kaishun Digital and IBM Introduce Memory Optimization Solution for HPC Enterprises
04/23
QuesTek Innovations Names Michelle Campbell as Chief Commercial Officer
04/23
Independent Emergency Physicians Invests in ConsensioHealth

More from: Life Sciences

04/23
InVita Expands HemaConnect to Support Cell and Gene Therapy Donor Programs
04/23
SamaCare Releases Benchmarks for Medical Benefit Prior Authorization Performance
04/23
Independent Emergency Physicians Invests in ConsensioHealth
04/23
Avenda Health's Unfold AI Added to Medicare Fee Schedule Across Western States
04/23
Heidi Launches in South Africa with 15,000 Clinicians Already Using Platform

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

AI’s Time-to-Market Quagmire: Why Enterprises Struggle to Scale AI Innovation

ModelOp

The 2025 AI Governance Benchmark Report by ModelOp provides insights from 100 senior AI and data leaders across various industries, highlighting the challenges enterprises face in scaling AI initiatives. The report emphasizes the importance of AI governance and automation in overcoming fragmented systems and inconsistent practices, showcasing how early adoption correlates with faster deployment and stronger ROI.

Read more

You May Also Like